Therapeutic Areas

Therapeutic Areas

We develop novel and differentiated oral small molecule therapies to patients suffering from diseases with significant unmet medical need.

We are a clinical stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.

Leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Therapeutic Areas

Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic steatohepatitis is a severe liver disease which affects 6-8% of adults in western industrialised nations and is on the rise around the globe.

Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of NASH: inflammation, steatosis, ballooning, and importantly fibrosis.

We are currently investigating lanifibranor in NATIVE, a Phase 2b clinical trial, with results expected in the first half of 2020.


MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.

Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.

In the recently completed iMProveS phase IIa study odiparcil confirmed its favourable safety profile and demonstrated efficacy in adult MPS VI patients, especially in tissues types not reached by standard of care.

Phase IIb trial in NASH, enrolment complete

Phase IIa in MPSVI, complete